The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review (Q38167693)

30 August 2017

title

The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review (English)

1 reference

30 August 2017

1 reference

2

Hans-Helmut König

1 reference

30 August 2017

Michael Sonntag

1

1 reference

30 August 2017

Alexander Konnopka

series ordinal

3

1 reference

30 August 2017

publication date

1 December 2013

1 reference

30 August 2017

1 reference

30 August 2017

volume

31

1 reference

30 August 2017

issue

12

1 reference

30 August 2017

page(s)

1131-1154

1 reference

A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

QALYs and mental health care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A review and critique of studies reporting utility values for schizophrenia-related health states.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of online computerised cognitive-behavioural therapy without support for depression in primary care: randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Incremental benefits and cost of coordinated anxiety learning and management for anxiety treatment in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of a minimal psychological intervention in chronically ill elderly patients with minor or mild to moderate depression: a randomized trial (the DELTA-study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of adherence therapy versus health education for people with schizophrenia: randomised controlled trial in four European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness Analysis of a Rural Telemedicine Collaborative Care Intervention for Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Updating and confirming an industry-sponsored pharmacoeconomic model: comparing two antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of screening for unhealthy alcohol use with % carbohydrate deficient transferrin: results from a literature-based decision analytic computer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of acute imipramine therapy versus two imipramine maintenance treatment regimens for panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Assessment of clinical guidelines for continuation treatment in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Screening for postnatal depression in primary care: cost effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of transcranial magnetic stimulation in the treatment of major depression: a health economics analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The cost-utility of screening for depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Mortality and treatment costs have a great impact on the cost-effectiveness of disease modifying treatment in Alzheimer's disease--a simulation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of ethyl-eicosapentaenoic acid in the treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of internet-based interventions for harmful alcohol use alongside a pragmatic randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of a disease management program for major depression in elderly primary care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of interpersonal psychotherapy for elderly primary care patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of problem-solving treatment in comparison with usual care for primary care patients with mental health problems: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of a stepped care programme to prevent depression and anxiety in residents in homes for the older people: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of brief cognitive behaviour therapy versus treatment as usual in recurrent deliberate self-harm: a decision-making approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive behavioural therapy in adolescents with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A pragmatic randomised controlled trial to evaluate the cost-effectiveness of a physical activity intervention as a treatment for depression: the treating depression with physical activity (TREAD) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Group art therapy as an adjunctive treatment for people with schizophrenia: a randomised controlled trial (MATISSE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cognitive therapy v. usual treatment for borderline personality disorder: prospective 6-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A randomized controlled trial of the cost-utility of second-generation antipsychotics in people with psychosis and eligible for clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost utility analysis of co-prescribed heroin compared with methadone maintenance treatment in heroin addicts in two randomised trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Effectiveness and cost-effectiveness of a stepped care intervention for alcohol use disorders in primary care: pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost utility of behavioural activation delivered by the non-specialist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

"Prehabilitation" prior to CABG surgery improves physical functioning and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of depression case management in small practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-utility of a walking programme for moderately depressed, obese, or overweight elderly women in primary care: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of brief psychodynamic-interpersonal therapy in high utilizers of psychiatric services.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of Internet-based cognitive behavior therapy vs. cognitive behavioral group therapy for social anxiety disorder: results from a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of therapist-delivered online cognitive-behavioural therapy for depression: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of 12-month therapeutic assertive community treatment as part of integrated care versus standard care in patients with schizophrenia treated with quetiapine immediate release (ACCESS trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A trial of problem-solving by community mental health nurses for anxiety, depression and life difficulties among general practice patients. The CPN-GP study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-Effectiveness of Sertindole among Atypical Antipsychotics in the Treatment of Schizophrenia in South Korea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of a primary care model for anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Dementia care costs and the patient's quality of life (QoL) in Taiwan: home versus institutional care services

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness analysis of an occupational therapy-led lifestyle approach and routine general practitioner's care for panic disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of escitalopram versus SNRIs in second-step treatment of major depressive disorder in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness evaluation in Sweden of escitalopram compared with venlafaxine extended-release as first-line treatment in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of diacetylmorphine versus methadone for chronic opioid dependence refractory to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Insomnia - treatment pathways, costs and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-utility of selective serotonin reuptake inhibitors for depression in primary care in Catalonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Fluoxetine and imipramine: are there differences in cost-utility for depression in primary care?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A cost-effectiveness analysis of modafinil therapy for psychostimulant dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A cost-utility analysis of pregabalin versus venlafaxine XR in the treatment of generalized anxiety disorder in Portugal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Model to assess the cost-effectiveness of new treatments for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The cost-utility of maintenance treatment with venlafaxine in patients with recurrent major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of psychotherapy for cluster C personality disorders: a decision-analytic model in the Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of St. John's wort (Hypericum perforatum) for the treatment of mild to moderate depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of treatment for alcohol problems: findings of the randomised UK alcohol treatment trial (UKATT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Exercise for depression in care home residents: a randomised controlled trial with cost-effectiveness analysis (OPERA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Out-patient psychotherapy for borderline personality disorder: cost-effectiveness of schema-focused therapy v. transference-focused psychotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-utility of brief psychological treatment for depression and anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-utility and cost-effectiveness of internet-based treatment for adults with depressive symptoms: randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of an integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A cost-utility analysis of psychoanalysis versus psychoanalytic psychotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of transcranial magnetic stimulation vs. electroconvulsive therapy for severe depression: a multi-centre randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Psychological treatment for insomnia in the regulation of long-term hypnotic drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of an improving access to psychological therapies service

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of a primary care depression intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of a primary care intervention for depressed females.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

One size fits some: the impact of patient treatment attitudes on the cost-effectiveness of a depression primary-care intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Mindfulness-based cognitive therapy for patients with medically unexplained symptoms: a cost-effectiveness study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The cost effectiveness of naltrexone added to cognitive-behavioral therapy in the treatment of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of quetiapine with lithium or divalproex for maintenance treatment of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of adjunctive quetiapine fumarate extended-release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Assessing the health and economic impact of galantamine treatment in patients with Alzheimer's disease in the health care systems of different countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Assessment of health economics in Alzheimer's disease (AHEAD): galantamine treatment in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of galantamine in a german context

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of donepezil treatment for Alzheimer's disease in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

When should functional neuroimaging techniques be used in the diagnosis and management of Alzheimer's dementia? A decision analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Potential cost-effectiveness of a family-based program in mild Alzheimer's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of functional imaging tests in the diagnosis of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of PET in the diagnosis of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The value of the managed entry of new drugs: a case study of donepezil

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-benefit analysis of second-generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Modeling the cost-effectiveness of galantamine for mild to moderately severe Alzheimer's disease in Korea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Multicomponent geriatric intervention for elderly inpatients with delirium: effects on costs and health-related quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-utility of treatment of bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The economic effect of Planet Health on preventing bulimia nervosa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The community psychiatric nurse in primary care: an economic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Evaluating the translation process of an Internet-based self-help intervention for prevention of depression: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Methylphenidate in children with hyperactivity: review and cost-utility analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of long-term treatment with eszopiclone for primary insomnia in adults: a decision analytical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of treatments for adolescent depression: results from TADS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of long-acting risperidone in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Incremental cost-effectiveness of a collaborative care intervention for panic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of computerised cognitive-behavioural therapy for anxiety and depression in primary care: randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of enhancing primary care depression management on an ongoing basis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness and cost-utility of cognitive therapy, rational emotive behavioral therapy, and fluoxetine (Prozac) in treating depression: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The cost-effectiveness of paliperidone extended release in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of memantine in moderate-to-severe Alzheimer's disease patients receiving donepezil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Estimation of utilities for the effects of depression from the SF-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The economic cost of brain disorders in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Measurement of health state utilities for economic appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Development of the EQ-5D-Y: a child-friendly version of the EQ-5D

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Comparison of EQ-5D and SF-6D utilities in mental health patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Putting the 'Q' in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A checklist for judging preference-based measures of health related quality of life: learning from psychometrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Condition-specific preference-based measures: benefit or burden?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Mapping for economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The time trade-off method: results from a general population study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The estimation of a preference-based measure of health from the SF-36.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Multiattribute and single-attribute utility functions for the health utilities index mark 3 system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Multi-attribute preference functions. Health Utilities Index

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Impact of atypical antipsychotics on quality of life in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The cost-effectiveness of methadone maintenance as a health care intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Evidence of cost-effective treatments for depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness analysis of pharmacological treatments in schizophrenia: critical review of results and methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Trends in the measurement of health utilities in published cost-utility analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-benefit analysis of drug treatment services: review of the literature*

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Community-based prevention programs for anxiety and depression in youth: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A critical review of selected pharmacoeconomic analyses of antidepressant therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Music and its effect on anxiety in short waiting periods: a critical appraisal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Escitalopram: a pharmacoeconomic review of its use in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Spotlight on the pharmacoeconomics of escitalopram in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic comparisons of the pharmacotherapy of depression: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Sertraline. A pharmacoeconomic evaluation of its use in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Newer hypnotic drugs for the short-term management of insomnia: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Evidence based review of escitalopram in treating major depressive disorder in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of mental health care interventions. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Risperidone: a review of its use in the treatment of bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Risperidone. A pharmacoeconomic review of its use in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Telemedicine for depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Costs and consequences of enhanced primary care for depression: systematic review of randomised economic evaluations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Internet-based mental health programs: a powerful tool in the rural medical kit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Mirtazapine. A pharmacoeconomic review of its use in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Escitalopram for the treatment of major depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

EQ-5D as a quality of life measure in people with dementia and their carers: evidence and key issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Group psychological therapies for depression in the community: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Pharmacoeconomics of cholinesterase inhibitors in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Varenicline: a pharmacoeconomic review of its use as an aid to smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A systematic review of the clinical and cost-effectiveness of memantine in patients with moderately severe to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-of-illness studies and cost-effectiveness analyses in anxiety disorders: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The cost-effectiveness and cost-benefit of screening and brief intervention for unhealthy alcohol use in medical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cognitive-behavioral treatment for panic disorder: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Intervening to reduce depression after birth: a systematic review of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Galantamine: a pharmacoeconomic review of its use in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Memantine: a review of its use in moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Effects of befriending on depressive symptoms and distress: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Utilities measured by rating scale, time trade-off, and standard gamble: review and reference for health care professionals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Escitalopram: a review of its use in the management of major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Disease management programs for depression: a systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-utility analysis studies of depression management: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

A systematic review of non-pharmacological treatments for depression in people with chronic physical health problems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The clinical effectiveness and cost-effectiveness of low-intensity psychological interventions for the secondary prevention of relapse after depression: a systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Annotation: Economic evaluations of child and adolescent mental health interventions: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluations of smoking cessation and relapse prevention programs for pregnant women: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The pharmaceutical economics of child psychiatric drug treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The health economics of attention deficit hyperactivity disorder in Germany. Part 2: Therapeutic options and their cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Is mental health economics important in geriatric psychiatry in developing countries?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Health state values for use in the economic evaluation of treatments for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Pharmaco-economics of community maintenance for opiate dependence: a review of evidence and methodology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Discharge planning in mental health care: a systematic review of the recent literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Collaborative care to improve the management of depressive disorders: a community guide systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of collaborative care for the treatment of major depressive disorder in primary care. A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost effectiveness of smoking-cessation therapies. Interpretation of the evidence-and implications for coverage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Escitalopram : a review of its use in the management of major depressive and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Clinical and economic outcomes--friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of cholinesterase inhibitor therapy for dementia: comparison of Alzheimer's disease and Dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Economic evaluation of interventions for problem drinking and alcohol dependence: cost per QALY estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Treating alcoholism reduces financial burden on care-givers and increases quality-adjusted life years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

The cost-effectiveness of increasing alcohol taxes: a modelling study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of guided self-help treatment for recurrent binge eating

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of long-term outpatient buprenorphine-naloxone treatment for opioid dependence in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Deep brain stimulation compared with methadone maintenance for the treatment of heroin dependence: a threshold and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of clozapine monitoring after the first 6 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of a multicondition collaborative care intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness and cost-utility of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Kosteneffektivitätsmodell eines ambulanten Hilfeangebotes für pflegende Angehörige von Demenzkranken

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cost-effectiveness of usual general practitioner care with or without antidepressant medication for patients with minor or mild-major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Cognitive behaviour therapy for improving social recovery in psychosis: Cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0107-9

Modelling lifetime QALYs and health care costs from different drinking patterns over time: a Markov model.

21 January 2018

1 reference

12 December 2020

Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2

1 reference

12 December 2020

Quality of life: experience with sertraline.

1 reference

12 December 2020

Modelling the cost effectiveness of antidepressant treatment in primary care

1 reference

12 December 2020

The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review.

1 reference

12 December 2020

Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy

1 reference

12 December 2020

Self-help books for depression: how can practitioners and patients make the right choice?

1 reference

12 December 2020

Does befriending by trained lay workers improve psychological well-being and quality of life for carers of people with dementia, and at what cost? A randomised controlled trial.

1 reference

12 December 2020

Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol

1 reference

12 December 2020

Group cognitive behavioural therapy for postnatal depression: a systematic review of clinical effectiveness, cost-effectiveness and value of information analyses

1 reference

12 December 2020

Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review

1 reference

12 December 2020

Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System

1 reference

12 December 2020

Outcome measures of antidepressive therapy.

1 reference

12 December 2020

A review of the use of health status measures in economic evaluation.

1 reference

12 December 2020

Cost-utility analysis of group living in dementia care

1 reference

12 December 2020

Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands

1 reference

12 December 2020

Befriending carers of people with dementia: a cost utility analysis

1 reference

12 December 2020

The cost-effectiveness of aripiprazole as adjunctive therapy in major depressive disorder: Thai economic model

1 reference

12 December 2020

Cost-effectiveness of eszopiclone for the treatment of adults with primary chronic insomnia.

1 reference

12 December 2020

Economic evaluation of a support program for caregivers of demented elderly

1 reference

12 December 2020

The costs and benefits of enhanced depression care to employers

1 reference

12 December 2020

Decision analysis of the cost-effectiveness of repetitive transcranial magnetic stimulation versus electroconvulsive therapy for treatment of nonpsychotic severe depression.

1 reference

12 December 2020

A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden

1 reference

12 December 2020

Health economic measures in schizophrenia research.

1 reference

12 December 2020

Cost-utility analysis of methadone maintenance treatment in Lithuania

1 reference

12 December 2020

Should "standard gamble" and "'time trade off" utility measurement be used more in mental health research?

1 reference

12 December 2020

Structural neuroimaging in psychosis: a systematic review and economic evaluation

1 reference

12 December 2020

Another study showing that two preference-based measures of health-related quality of life (EQ-5D and SF-6D) are not interchangeable. But why should we expect them to be?

1 reference

12 December 2020

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

1 reference

12 December 2020

A systematic literature review of the effectiveness of non-pharmacological interventions to prevent wandering in dementia and evaluation of the ethical implications and acceptability of their use.

1 reference

12 December 2020

Cost-effectiveness of improving primary care treatment of late-life depression

1 reference

12 December 2020

A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression.

1 reference

12 December 2020

The use of CT scanning in dementia. A systematic review

1 reference

12 December 2020

Cost-effectiveness of interventions for depressed Latinos

1 reference

12 December 2020

Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation

1 reference

12 December 2020

A general health policy model: update and applications

1 reference

12 December 2020

Economic outcomes of eszopiclone treatment in insomnia and comorbid major depressive disorder

1 reference

12 December 2020

Cost-effectiveness and net benefit of enhanced treatment of depression for older adults with diabetes and depression

1 reference

12 December 2020

Treatment for inhalant dependence and abuse

1 reference

12 December 2020

"The trouble with QALYs...".

1 reference

12 December 2020

Psychological interventions for postnatal depression: cluster randomised trial and economic evaluation. The PoNDER trial.

1 reference

12 December 2020

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

1 reference

12 December 2020

The effectiveness and cost-effectiveness of parent training/education programmes for the treatment of conduct disorder, including oppositional defiant disorder, in children

1 reference

12 December 2020

[Health economics of psychological diseases]

1 reference

12 December 2020

General health status measures for people with cognitive impairment: learning disability and acquired brain injury.

1 reference

12 December 2020

Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care

1 reference

12 December 2020

Cost-effectiveness of quality improvement programs for patients with subthreshold depression or depressive disorder

1 reference

12 December 2020

Cost-effectiveness of psychotherapy for cluster B personality disorders

1 reference

12 December 2020

Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine

1 reference

12 December 2020

Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland

1 reference

12 December 2020

Cost-effectiveness of a health intervention program with risk reductions for getting demented: results of a Markov model in a Swedish/Finnish setting

1 reference

12 December 2020

The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder

1 reference

12 December 2020

Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression

1 reference

12 December 2020

Cost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorder

1 reference

12 December 2020

Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison

1 reference

12 December 2020

A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia.

1 reference

12 December 2020

Home treatment for mental health problems: a systematic review

1 reference

12 December 2020

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

1 reference

12 December 2020

Cost-effectiveness of treatments for major depression in primary care practice

1 reference

12 December 2020

Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia

1 reference

12 December 2020

[Economic aspects of psychotherapy management in psychosomatics and psychiatry. A systematic survey of the literature]

1 reference

12 December 2020

Self-directed cognitive behavioural therapy for adults with diagnosis of depression: systematic review of clinical effectiveness, cost-effectiveness, and guidelines.

1 reference

12 December 2020

A cost-effectiveness analysis of alcohol prevention targeting licensed premises

1 reference

12 December 2020

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder

1 reference

12 December 2020

Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation

1 reference

12 December 2020

The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

1 reference

12 December 2020

Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings

1 reference

12 December 2020

Cost-utility of 2 maintenance treatments for older adults with depression who responded to a course of electroconvulsive therapy: results from a decision analytic model

1 reference

12 December 2020

Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada

1 reference

12 December 2020

Outcome measures and needs assessment tools for schizophrenia and related disorders

1 reference

12 December 2020

The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone

1 reference

12 December 2020

[Measuring preferences of psychiatric patients]

1 reference

12 December 2020

Cost-effectiveness of integrated care for elderly depressed patients in the PRISM-E study.

1 reference

12 December 2020

A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety

1 reference

12 December 2020

A systematic review of atypical antipsychotic drugs in schizophrenia.

1 reference

12 December 2020

Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin

1 reference

12 December 2020

Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK

1 reference

12 December 2020

Insomnia treatment in New Zealand

1 reference

12 December 2020

Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications

1 reference

12 December 2020

Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers

1 reference

12 December 2020

Randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of selective serotonin reuptake inhibitors plus supportive care, versus supportive care alone, for mild to moderate depression with somatic symptoms in primar

1 reference

12 December 2020

Cost-effectiveness of quetiapine plus mood stabilizers compared with mood stabilizers alone in the maintenance therapy of bipolar I disorder: results of a Markov model analysis

1 reference

12 December 2020

[Health economics and evaluation of schizophrenic psychoses in Germany]

1 reference

12 December 2020

Economic consequences of alternative medication strategies in first episode non-affective psychosis

1 reference

12 December 2020

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

1 reference

12 December 2020

Quality of life and drug costs associated with switching antipsychotic medication to once-daily extended release quetiapine fumarate in patients with schizophrenia

1 reference

12 December 2020

Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline

1 reference

12 December 2020

Costs and Cost-Effectiveness of Family CBT Versus Individual CBT in Clinically Anxious Children

1 reference

12 December 2020

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

1 reference

12 December 2020

Cost-effectiveness of an intervention to prevent depression in at-risk teens

1 reference

12 December 2020

Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis.

1 reference

12 December 2020

A Markov cost-utility analysis of escitalopram and duloxetine for the treatment of major depressive disorder

1 reference

12 December 2020

The cost-effectiveness of atypicals in the UK

1 reference

12 December 2020

A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial

1 reference

12 December 2020

Cost effectiveness of memantine in Alzheimer's disease in the UK.

1 reference

12 December 2020

Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: a post hoc cost-effectiveness analysis in usual medical practice in Spain

1 reference

12 December 2020

Cost-effectiveness of methadone maintenance treatment for HIV-positive drug users in Vietnam

1 reference

12 December 2020

[Pharmacoeconomics of the New Antidepressants and Antipsychotics]

1 reference

12 December 2020

Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease.

1 reference

12 December 2020

A pharmacoeconomic analysis of compliance gains on antipsychotic medications

1 reference

12 December 2020

Modeling valuations for EuroQol health states

1 reference

12 December 2020

Compulsory community and involuntary outpatient treatment for people with severe mental disorders

1 reference

12 December 2020

Developing thai economic model to study cost-effectiveness of switching to bupropion compared to combination with bupropion after the failure of an SSRI for major depressive disorder

1 reference

12 December 2020

Should clozapine continue to be restricted to third-line status for schizophrenia?: a decision-analytic model

1 reference

12 December 2020

10.1007/S40273-013-0107-9

Identifiers

DOI

1 reference

30 August 2017

1 reference